Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease
http://www.prnewswire.com/news-relea...111255279.html
Abraham Lieberman, MD, the study's principal investigator and Director of the Muhammad Ali Parkinson's Center, commented, "NP002 represents an innovative approach to a common side effect in treating Parkinson's disease and has opened up new ideas on how to approach dyskinesias. The early study results of NP002 in patients with Parkinson's show promising trends in reducing dyskinesias and in improving gait. I am encouraged by these results and believe they provide a key piece in understanding and addressing the mechanism of dyskinesias in many of our patients with Parkinson's disease."